Engineered extracellular vesicles with osteoblast-targeting capacity ameliorate postmenopausal osteoporosis via activating mitophagy and restoring mitochondrial homeostasis
Chemical Engineering Journal · 2026-11 · 547 · 180742
DOI: 10.1016/j.cej.2026.180742 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Engineering Journal, 2026-11. Verfasst von Xin Ge und 6 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Key Research and Development Projects of Shaanxi Province, Natural Science Basic Research Program of Shaanxi Province.
Abstract (Originalsprache)
Osteoporosis (OP) is a growing global age-related metabolic bone disorder characterized by progressive bone loss, deteriorated trabecular microarchitecture, and elevated fragility fracture risk. Current first-line pharmacotherapies for OP are severely limited by long-term adverse events, narrow therapeutic windows, and failure to fully restore impaired bone homeostasis. Mesenchymal stem cell-derived small extracellular vesicles (sEVs) hold great promise for bone regenerative medicine, while their clinical translation for OP treatment is severely hampered by insufficient bone-targeting specificity and low in vivo bioavailability. Herein, we engineered a dual-functional cell-free nanoplatform based on sEVs derived from melatonin-preconditioned stem cells from human exfoliated deciduous teeth (SHED) with Angiopep-2 (Ang2pep) surface functionalization (M-Ang2pep-SHED-sEVs) for targeted OP therapy. Single-cell RNA sequencing (scRNA-seq) of clinical samples uncovered that impaired mitophagy and mitochondrial dysfunction are crucial hallmarks of osteoblasts in OP, and identified low-density lipoprotein receptor-related protein 1 (LRP1), the cognate receptor of Angiopep-2, as a membrane protein highly enriched in osteoblasts. Angiopep-2 surface modification conferred sEVs with enhanced osteoblast-targeting capacity, achieving an increase in bone tissue accumulation in vivo. Melatonin preconditioning optimized the protein cargo profile of sEVs, significantly enhancing their pro-osteogenic and mitophagy-regulating bioactivity without compromising targeting efficiency and biosafety. We further demonstrated that M-Ang2pep-SHED-sEVs effectively alleviated bone loss in ovariectomy-induced OP mouse models by increasing mitophagy to restore mitochondrial homeostasis and osteogenic function in impaired osteoblasts, which was validated by in vitro and in vivo loss-of-function assays. This work presents a promising, and targeted cell-free nanotherapeutic strategy for clinical OP management, and provides new insights into mitophagy-targeted therapy for metabolic bone diseases.
Förderung
- Key Research and Development Projects of Shaanxi Province
- Natural Science Basic Research Program of Shaanxi Province
Zitieren
APA
Ge, X., Zhao, Y., Liu, Y., Zhang, B., Wang, J., Di, T., & Chen, Y. (2026). Engineered extracellular vesicles with osteoblast-targeting capacity ameliorate postmenopausal osteoporosis via activating mitophagy and restoring mitochondrial homeostasis. Chemical Engineering Journal, 547, 180742. https://doi.org/10.1016/j.cej.2026.180742
Vancouver
Ge X, Zhao Y, Liu Y, Zhang B, Wang J, Di T, et al. Engineered extracellular vesicles with osteoblast-targeting capacity ameliorate postmenopausal osteoporosis via activating mitophagy and restoring mitochondrial homeostasis. Chemical Engineering Journal. 2026;547:180742. doi:10.1016/j.cej.2026.180742
BibTeX
@article{Ge2026,
author = {Ge, Xin and Zhao, Ying and Liu, Yuhan and Zhang, Baize and Wang, Junhui and Di, Tiankai and Chen, Yujiang},
title = {Engineered extracellular vesicles with osteoblast-targeting capacity ameliorate postmenopausal osteoporosis via activating mitophagy and restoring mitochondrial homeostasis},
journal = {Chemical Engineering Journal},
year = {2026},
volume = {547},
pages = {180742},
doi = {10.1016/j.cej.2026.180742}
}
EUVIMED